Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: SurrogateEndpoints and Design of Clinical Trials

Guest Editors

Gary J. Kelloff
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Charles W. Boone
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Michelle F. Mitchell
Department of Gynecological Oncology
University of Texas
M.D. Anderson Cancer Center
Houston, TX

C. Paul Morrow
Department of Gynecological Oncology
University of Southern California
Medical Center
Los Angeles, CA
Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials

Guest Editors

Gary J. Kelloff, MD, Charles W. Boone, MD, PhD, C. Paul Morrow, MD, and Michele Follen Mitchell, MD, MS

INTRODUCTION

Strategies for Phase II Cancer Chemoprevention Trials: Cervix, Endometrium, and Ovary
Gary J. Kelloff, Charles W. Boone, James A. Crowell, Susan G. Nayfield, Ernest Hawk, Vernon E. Steele, Ronald A. Lubet, and Caroline C. Sigman 1

Role of the Pathologist in Biomarker Studies
Edward J. Wilkinson and James B. Hendricks 10

A Phase II Chemoprevention Trial Design to Identify Surrogate Endpoint Biomarkers in Breast Cancer
Kapil Dhingra 19

QUANTITATIVE MEASUREMENTS IN PATHOLOGY

Computer-Assisted Pathology of Intraepithelial Adenocarcinoma and Related Lesions: 3-D Distribution, Structural Aberration and Discrimination
Tohru Takahashi, Ryoji Chiba, Masuko Mori, Tohru Furukawa, Masanori Suzuki, and Fumiaki Tezuka 25
Cervical Cell Recognition and Morphometric Grading by Image Analysis
James W. Bacus ................................................................. 33

Image Cytometry and Chemoprevention in Cervical Cancer
Branko Palcic, David M. Garner, and Calum E. MacAulay ............ 43

CERVIX

The Molecular Biology of Cervical Cancer
Karl Münger ................................................................. 55

Perspective on Cervical Cancer: Why Prevent?
C. Paul Morrow and Wendy Cozen ........................................ 61

Cervical Intraepithelial Neoplasia
Christopher P. Crum and Catherine M. McLachlin ..................... 71

Inhibition of Proliferation and Induction of Apoptosis in Cervical Carcinoma Cells by Retinoids: Implications for Chemoprevention
Nobuhiko Oridate, Dafna Lotan, Michele Follen Mitchell, Waun K. Hong,
and Reuben Lotan ............................................................ 80

Polyamines as Biomarkers of Cervical Intraepithelial Neoplasia
Kenji Nishioka, Alejandro B. Melgarejo, Rosanna R. Lyon,
and Michele Follen Mitchell ................................................ 87

Nutrient Antioxidants in the Pathogenesis and Prevention of Cervical Dysplasias and Cancer
Seymour L. Romney, Prabhudas R. Palan, Jayasri Basu,
and Magdy Mikhail ........................................................... 96

Chemoprevention Trials in the Cervix: Design, Feasibility, and Recruitment
Michele Follen Mitchell, Walter N. Hittelman, Reuben Lotan, Kenji Nishioka,
Guillermo Tortolero-Luna, Rebecca Richards-Kortum, and Waun K. Hong, ... 104

Surrogate Endpoint Biomarkers for Cervical Cancer Chemoprevention Trials
Mack T. Ruffin IV, Mohammed S. Ogaily, Carolyn M. Johnston,
Lucie Gregoire, Wayne D. Lancaster, and Dean E. Brenner .............. 113

Statistical Techniques for Diagnosing CIN Using Fluorescence Spectroscopy: SVD and CART
E. Neely Atkinson, Michele Follen Mitchell, Nirmala Ramanujam,
and Rebecca Richards-Kortum .............................................. 125

iv (continued)
ENDOMETRIUM

Clinical Aspects of Risk in Women With Endometrial Carcinoma
Thomas W. Burke, Wesley C. Fowler, Jr., and C. Paul Morrow .......................... 131

The Role of Computerized Morphometric and Cytometric Feature Analysis in Endometrial Hyperplasia and Cancer Prognosis
Jan P.A. Baak ........................................................................................................... 137

Quantitative Cytopathology of Endometrial Lesions
Fumiaki Tezuka, Ryoji Chiba, and Tohru Takahashi ............................................. 147

Epidemiology of Endometrial Neoplasia
David Schottenfeld .................................................................................................. 151

Endometrial Cancer Chemoprevention: Implications of Diverse Pathways of Carcinogenesis
Mark E. Sherman, Susan Sturgeon, Louise Brinton, and Robert J. Kurman ........... 160

Detection of Occult Endometrial Carcinoma
Leopold G. Koss ....................................................................................................... 165

Biomarkers in the Endometrium
Andrew Berchuck ..................................................................................................... 174

Uterine Neoplasms in Patients Treated with Tamoxifen
Elvio G. Silva, Carmen Tornos, Anais Malpica, and Michele Follen Mitchell .......... 179

Potential Criteria for Cohort Selection in Chemoprevention Trials of Uterine Adenocarcinoma
Vicki V. Baker .......................................................................................................... 184

OVARY

Prospective on Ovarian Cancer: Why Prevent?
William Hoskins ...................................................................................................... 189

The Epidemiology of Ovarian Cancer
Guillermo Tortolero-Luna and Michele Follen Mitchell ......................................... 200

Pathology of Ovarian Cancer Precursors
Robert E. Scully ...................................................................................................... 208

(continued)
Molecular Approaches to Prevention and Detection of Epithelial Ovarian Cancer
Robert C. Bast, Jr., Cindar M. Boyer, Feng Ji Xu, Jon Wiener, Robert Dabel, Robert Woolas, Ian Jacobs, and Andrew Berchuck ........................................... 219

Biomarkers in the Ovary
Andrew Berchuck .................................................. 223

Screening for Ovarian Cancer: What Are the Optimal Surrogate Endpoints for Clinical Trials?
Beth Y. Karlan ....................................................... 227

Early Detection and Screening For Ovarian Cancer
Peter E. Schwartz, Joseph T. Chambers, and Kenneth J. Taylor .................. 233

Office Laparoscopy as a Screening Tool for Early Detection of Ovarian Cancer
Carolyn D. Runowicz ............................................. 238

Potential Criteria for Cohort Selection in Chemoprevention Trials of Epithelial Ovarian Cancer
Vicki V. Baker ..................................................... 243

Author Index ....................................................... 247

Subject Index ..................................................... 249

FRONT COVER: Squamous carcinoma of the cervix (left), adenocarcinoma of the endometrium (middle), and papillary serous carcinoma of the ovary (right). Submitted by Dr. Michele Follen Mitchell.

BACK COVER: Cervical neoplasia is associated with infection by specific high-risk human papilloma-virus (HPV) types. This drawing shows the interaction of high-risk HPV E6 and E7 protein products with critical regulatory steps in cell cycle progression as described by Dr. Karl Münger (see Münger, this supplement). Several opportunities for chemopreventive intervention against HPV-associated carcinogenesis are suggested—blocking the interaction of E6 protein with p53 and E7 protein with pRB and inhibiting cyclin-cyclin dependent kinases complexes (cyclin-CDKs).